文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

母体疫苗与长效单克隆抗体对生命早期呼吸道合胞病毒疾病负担的效果:动态模型研究的范围综述

Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies.
PubMed 文献 · Vaccine · 2025-11-07

本范围综述调查了估算母体疫苗或长效单克隆抗体对2岁以下儿童群体水平影响的动态模型研究,聚焦中高收入与高收入地区。共回顾210篇文章,7篇符合标准,其中2篇仅建模母体疫苗策略,1篇仅建模长效单克隆抗体策略,4篇同时建模两者。所有研究均发现母体疫苗和/或长效单克隆抗体可显著减少12个月以下儿童的呼吸道合胞病毒住院。

要点

  • 在全年和季节性策略中,母体疫苗与单克隆抗体分别使3个月以下婴儿每年每1000名儿童避免5-21例和11-32例呼吸道合胞病毒住院。
  • 对应避免住院比例分别约为10-53%和32-70%。
  • 单克隆抗体的预测影响大于疫苗,因假设的覆盖率和效力更高。

核心结论

  • 所有研究均发现母体疫苗和/或长效单克隆抗体可显著减少12个月以下儿童的呼吸道合胞病毒住院。
  • 研究间结果具有广泛一致性,且所有研究均捕捉到年龄较大儿童中影响下降。
  • 由于假设的覆盖率和效力更高,单克隆抗体的预测影响大于疫苗。
  • 母体免疫的假设存在差异,改善该机制的证据基础将有益。

研究设计与样本

  • 范围综述,调查估算母体疫苗或长效单克隆抗体对2岁以下儿童群体水平影响的动态模型研究,聚焦中高收入与高收入地区。
  • 共回顾210篇文章,7篇符合标准;其中2篇仅建模母体疫苗策略,1篇仅建模长效单克隆抗体策略,4篇同时建模两者。

主要发现

  • 在全年和季节性策略建模中,母体疫苗使3个月以下婴儿每年每1000名儿童避免5-21例呼吸道合胞病毒住院,对应避免住院比例约10-53%。
  • 在全年和季节性策略建模中,单克隆抗体使3个月以下婴儿每年每1000名儿童避免11-32例呼吸道合胞病毒住院,对应避免住院比例约32-70%。
  • 7项研究中有6项明确捕捉了婴儿自然母体来源免疫,但其幅度和持续时间差异很大。
  • 所有研究均捕捉到年龄较大儿童中影响下降。

关键数值与推荐

  • 母体疫苗:3个月以下婴儿每年每1000名儿童避免5-21例呼吸道合胞病毒住院,避免住院比例约10-53%。
  • 单克隆抗体:3个月以下婴儿每年每1000名儿童避免11-32例呼吸道合胞病毒住院,避免住院比例约32-70%。

局限性

  • 母体免疫的假设存在差异,改善该机制的证据基础将有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of respiratory illness and hospitalisation in young children. New interventions for preventing severe RSV in early life, namely a maternal vaccine and a long-acting monoclonal antibody, have recently been approved and are available for use. Mathematical models of RSV transmission have been used to predict the impact of novel interventions, in anticipation of product licensure, and to model the impact of interventions once available. However, models vary in structure, parameterisation, assumptions, and scenarios simulated. METHODS: In this scoping review, we surveyed dynamic modelling studies estimating the prospective population-level impact of an RSV maternal vaccine or a long-acting monoclonal antibody in children <2 years, focussing on upper-middle- and high-income settings. We extracted data on model structures, assumptions, and parameterisation, and synthesised the estimates of immunisation impact across studies. FINDINGS: Of the 210 articles reviewed, seven met our criteria. Two studies modelled only a maternal vaccination strategy, one modelled a long-acting monoclonal strategy, and four modelled both. Across the year-round and seasonal strategies modelled, estimates ranged from 5 to 21 and 11 to 32 annual RSV hospitalisations per 1,000 children averted for a maternal vaccine and a monoclonal antibody respectively in infants aged <3 months, corresponding to approximately 10-53 % and 32-70 % hospitalisations averted. Six of the studies explicitly captured natural maternally-derived immunity in infants, but the magnitude and duration varied widely. INTERPRETATION: All studies found that either a maternal vaccine and/or a long-acting monoclonal antibody could significantly reduce RSV hospitalisations in children younger than 12 months. We identified broad consistency in results across studies, and all studies captured declining impact in older children. Predicted impact was larger for a monoclonal antibody compared to a vaccine, due to higher assumed coverage and efficacy. Assumptions around maternal immunity varied, and improving the evidence base for this mechanism would be beneficial.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bicego A, Wood JG, Newall AT, et al. Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies. Vaccine. 2025. PMID: 41205402. doi:10.1016/j.vaccine.2025.127868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。